Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model
Kosten-Nutzen-Analyse des Wechsels von Nusinersen zu Risdiplam bei Patient:innen mit spinale Muskelatrophie in Kroatien: ein diskretes Ereignis-Simulationsmodell
British Journal of Clinical Pharmacology · 14.12.2025
DOI: 10.1002/bcp.70379 ↗Auf einen Blick
Ein Simulationsmodell zeigte für SMA-Typen 1–3 wirtschaftliche Vorteile des Wechsels von Nusinersen zu Risdiplam. Für Typ 1 war der Wechsel dominant.
Fragestellung
Wie ist die Kosten-Nutzen-Bilanz eines Wechsels von Nusinersen zu Risdiplam im Vergleich zur Fortführung von Nusinersen bei SMA?
Methode
Diskretes Ereignis-Simulationsmodell für 3 Patient:innengruppen mit SMA Typ 1–3; Perspektive des Croatian Health Insurance Fund; Zeithorizont 80 Jahre; Sensitivitätsanalyse mit Monte-Carlo-Simulation.
Ergebnisse
ICER Nusinersen zu Risdiplam-Wechsel vs. Nusinersen: Typ 1 EUR-136930 ± 82 336; Typ 2 EUR 2681860 ± 321 859; Typ 3 EUR 2576667 ± 676 078. Positiver Net Monetary Benefit in allen 3 Typen.
Einschränkungen
Marktkräfte können die Preisentwicklung deutlich beeinflussen; die Ergebnisse sollten unter Berücksichtigung inhärenter Unsicherheiten interpretiert werden.
Schlussfolgerung der Autor:innen
Die Kosteneffektivität des Wechsels von Nusinersen zu Risdiplam ist für alle SMA-Typen erkennbar. Weitere Forschung zum Langzeiteffekt ist nötig, um Unsicherheiten zu adressieren.
Kernaussagen
- Wechsel zu Risdiplam war für SMA-Typ 1 dominant
- Positiver Net Monetary Benefit in allen 3 SMA-Typen
- Preisänderungen können die Ergebnisse wesentlich beeinflussen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 14.12.2025. Verfasst von Andrej Belančić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients. There is reason to believe that there are economic benefits of switching patients from nusinersen to risdiplam, especially because real‐world analysis has shown non‐inferiority in clinical outcomes along with a favourable safety profile of switching.
Aim
To conduct the cost‐utility analysis of switching from nusinersen to risdiplam.
Methods
A discrete event simulation model was created for three different groups of patients with SMA (types 1–3), comparing the cost‐utility of nusinersen to the risdiplam switch and continuing nusinersen therapy. Analysis was conducted from the perspective of the Croatian Health Insurance Fund for the time horizon of 80 years. A deterministic, one‐way, one‐factor sensitivity analysis was carried out using the Monte Carlo simulation.
Results
The incremental cost‐effectiveness ratio of nusinersen to risdiplam switch versus staying on nusinersen was EUR‐136930 ± 82 336 for type 1 SMA (i.e. the switch dominated), for type 2 SMA it was EUR 2681860 ± 321 859, and for type 3 SMA it was EUR 2576667 ± 676 078. For all three types of SMA, switching to risdiplam showed positive net monetary benefit (type 1: EUR 35449 ± 17 113; type 2: EUR 799264 ± 30 765; type 3: EUR 767498 ± 7283). Market forces may substantially impact pricing dynamics; therefore, these results should be interpreted with consideration of inherent uncertainties.
Conclusion
The cost‐effectiveness of switching from nusinersen to risdiplam is evident across all SMA types. Further research on the long‐term impact of switching treatments in SMA is essential to address uncertainties and optimize cost‐effective therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia.
- Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
- Athens, Greece.
- Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
ORCID-Profile: Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić
Zitieren
APA
Belančić, A., Stević, I., Gkrinia, E. M. M., Vitezić, D., & Janković, S. (2025). Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70379
Vancouver
Belančić A, Stević I, Gkrinia EMM, Vitezić D, Janković S. Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70379
BibTeX
@article{Belani2025,
author = {Belančić, Andrej and Stević, Ivana and Gkrinia, Elvira Meni Maria and Vitezić, Dinko and Janković, Slobodan},
title = {Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70379}
}
EUVIMED